InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI and New York, NY, USA. Source
No articles found.
Rhythm is a biopharmaceutical company dedicated to changing how rare genetic disor...
Rhythm is a biopharmaceutical company dedicated...
Aravive is developing treatments designed to halt progression of life-threatening ...
Aravive is developing treatments designed to ha...
Insulet Corporation is an innovative medical device company based in Acton, Massac...
Insulet Corporation is an innovative medical de...
Eiger is a late stage biopharmaceutical company focused on the development and com...
Eiger is a late stage biopharmaceutical company...
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal a...
Immunomedics is a clinical-stage biopharmaceuti...
We are a clinical-stage biopharmaceutical company committed to realizing the promi...
We are a clinical-stage biopharmaceutical compa...
Midatech is an international specialty pharmaceutical company focused on the devel...
Midatech is an international specialty pharmace...
Hutchison China MediTech Limited, known as Chi-Med, is an innovative biopharmaceut...
Hutchison China MediTech Limited, known as Chi-...
We are a biotechnology company developing novel immunotherapy treatments for cance...
We are a biotechnology company developing novel...
Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...
Dynavax Technologies Corporation (Nasdaq: DVAX)...
Join the National Investor Network and get the latest information with your interests in mind.